Short description
Philadelphia-based biotechnology company .
Description
We are a clinical stage biopharmaceutical company engaged in the discovery and development of synthetic derivatives of newly discovered endogenous hormones that target misfolded proteins, including alpha-synuclein in Parkinson’s Disease, or PD, amyloid beta and tau in Alzheimer’s Disease, or AD, as well as targeting insulin resistance which is central to the pathology of Type 2 Diabetes, or T2D, and AD. Our vision is to prevent the onset of these neurodegenerative and metabolic disorders, as well as to slow their progression.
Total funding
$$121212
Sign in for full access
Location
Philadelphia, Pennsylvania, United States, North America
Founded on
January 1, 2016
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Absolutely Noaccess, Absolutely Noaccess
Sign in for full access
Founders
Denise Barbut, Michael Zasloff, William Kinney